These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30832716)

  • 1. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
    Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
    J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
    Trinh B; Sanchez GO; Herzig P; Läubli H
    J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
    Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
    J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
    Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
    Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
    [No Abstract]   [Full Text] [Related]  

  • 8. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
    Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
    J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
    Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
    J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
    Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
    Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
    Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
    [No Abstract]   [Full Text] [Related]  

  • 15. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
    Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
    Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment.
    Amini-Adle M; Piperno M; Tordo J; Thomas L; Dalle S; Dubois V; Marabelle A
    Arthritis Rheumatol; 2018 Aug; 70(8):1358. PubMed ID: 29579372
    [No Abstract]   [Full Text] [Related]  

  • 17. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.